GUD:CC News and Press, Knight Therapeutics Inc. From 01/04/24

MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY ® in Canada. IMVEXXY ® (estradiol vaginal inserts) is approved for the treatment of postme...

MONTREAL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ("Supernus"), a biopharm...

2023-12-11 19:00:00 ET Before a certain global health crisis hit the markets, it seemed that everyone was investing in the energy, tech, and financial services industries. As world economies almost came to an abrupt halt amid COVID-19, stocks in other areas of the economy came to th...

MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2023. All currency amounts ar...

K-Bro Linen Inc. (KBL:CA) is expected to report $0.57 for Q3 2023 Yellow Pages Limited (Y:CA) is expected to report for Q3 2023 Ascot Resources Ltd. (AOT:CA) is expected to report for Q3 2023 Park Lawn Corporation (PLC:CA) is expected to report $0.27 for Q3 2023 Hut 8 Mining Corp....

Knight Therapeutics Inc. (GUD:CA) is expected to report $0.03 for Q3 2023

MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Following the re...

MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Mar...

MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, t...

MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada’s Top Growing Companies. Canada’s Top Growing Compani...